









Markets
/
Stocks
/
nasdaq-gyre
/

Gyre Therapeutics Inc

GYRE

7.210USD

-0.130-1.77%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

655.32MMarket Cap

98.53P/E TTM



Gyre Therapeutics Inc

7.210

-0.130-1.77%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Gyre Therapeutics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Gyre Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

89 / 407

Overall Ranking

211 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

18.000

Target Price

+149.65%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Gyre Therapeutics Inc Highlights

StrengthsRisks

Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 13219.52% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 153.67, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 3.45M shares, increasing 13.02% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.15M shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 9.17, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 26.77M, representing a year-over-year increase of 6.13%, while its net profit experienced a year-over-year increase of 87.47%.

Score

Industry at a Glance

Previous score

9.17

Change



Financials

9.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.78

Key Metrics

Free cash flow

No Data

Gyre Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 5.12, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 153.67, which is 23.02% below the recent high of 189.05 and 125.41% above the recent low of -39.04.

Score

Industry at a Glance

Previous score

5.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 89/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Gyre Therapeutics Inc is 18.00, with a high of 20.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

18.000

Target Price

+149.65%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Gyre Therapeutics Inc

GYRE

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.52, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 8.71 and the support level at 6.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.57

Change

-0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.200

Sell

RSI(14)

40.790

Neutral

STOCH(KDJ)(9,3,3)

10.767

Oversold

ATR(14)

0.327

High Vlolatility

CCI(14)

-109.910

Sell

Williams %R

93.233

Oversold

TRIX(12,20)

-0.166

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

7.310

Sell

MA10

7.525

Sell

MA20

7.926

Sell

MA50

7.721

Sell

MA100

7.653

Sell

MA200

8.777

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 3.80%, representing a quarter-over-quarter decrease of 95.92%. The largest institutional shareholder is The Vanguard, holding a total of 1.15M shares, representing 1.27% of shares outstanding, with 238.81% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

GNI Group Ltd

72.77M

+13.70%

Luo (Ying)

2.84M

Ma (Songjiang)

2.84M

-3.64%

The Vanguard Group, Inc.

Star Investors

1.15M

+4.85%

BlackRock Institutional Trust Company, N.A.

765.74K

+51.05%

Ye (Weiguo)

700.00K

+7.69%

Geode Capital Management, L.L.C.

401.71K

+28.62%

State Street Investment Management (US)

177.77K

+38.05%

SBI Securities Co., Ltd.

232.30K

+87.90%

Northern Trust Investments, Inc.

141.25K

+32.13%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 3.14, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.89. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.